RenovoRx is a clinical-stage biopharmaceutical company focused on developing targeted combination therapies designed to improve treatment outcomes for cancer patients. The company's primary development effort centers on RenovoCath, a localized chemotherapy delivery system that combines gemcitabine with catheter-based administration technology. RenovoCath is currently in Phase III clinical trials for the treatment of locally advanced pancreatic cancer, representing the company's lead product candidate.
The company operates with a small workforce of 10 full-time employees and is headquartered in Mountain View, California. As a clinical-stage entity, RenovoRx has not yet generated revenue from product sales and remains dependent on funding mechanisms typical of early-stage biopharmaceutical firms. The company was incorporated in Delaware and founded in 2009, with shares listed on Nasdaq.
Fiscal years are as reported by the company and may not align with the calendar year. For example, Apple's FY 2024 ends in September 2024.
| Fiscal Year | EPS Diluted | EPS Basic | YoY | |
|---|---|---|---|---|
| 2024 | $-0.40 | $-0.40 | +59.6% | |
| 2023 | $-0.99 | $-0.99 | +9.2% | |
| 2022 | — | $-1.09 | — | |
| 2021 | — | — | — |